<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16986</article-id><article-id pub-id-type="doi">10.36691/RJA16986</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Preclinical study of reproductive toxicity of a drug based on an aqueous solution of fullerene С<sub>60</sub> for the treatment of food allergies</article-title><trans-title-group xml:lang="ru"><trans-title>Доклиническое изучение репродуктивной токсичности лекарственного средства на основе водного раствора фуллерена С<sub>60</sub>, предназначенного для терапии пищевой аллергии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8457-7391</contrib-id><contrib-id contrib-id-type="spin">2952-1038</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovaleva</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Ковалева</surname><given-names>Елена Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>e-kovaleva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-1901-7244</contrib-id><contrib-id contrib-id-type="spin">5919-6840</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>Yulia V.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>Юлия Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ivanova-juliya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4826-7092</contrib-id><contrib-id contrib-id-type="spin">9404-4895</contrib-id><name-alternatives><name xml:lang="en"><surname>Onatsky</surname><given-names>Nikolay M.</given-names></name><name xml:lang="ru"><surname>Онацкий</surname><given-names>Николай Максимович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>onatsky@toxicbio.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-4617-1141</contrib-id><contrib-id contrib-id-type="spin">7381-4940</contrib-id><name-alternatives><name xml:lang="en"><surname>Shangaraeva</surname><given-names>Vitaliia A.</given-names></name><name xml:lang="ru"><surname>Шангараева</surname><given-names>Виталия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>vitaliyablik@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1926-6090</contrib-id><contrib-id contrib-id-type="spin">5426-1810</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorshenin</surname><given-names>Denis S.</given-names></name><name xml:lang="ru"><surname>Горшенин</surname><given-names>Денис Cергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dgorhenin63@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0981-5540</contrib-id><contrib-id contrib-id-type="spin">3080-0926</contrib-id><name-alternatives><name xml:lang="en"><surname>Baraboshkina</surname><given-names>Elena N.</given-names></name><name xml:lang="ru"><surname>Барабошкина</surname><given-names>Елена Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>en.baraboshkina@nrcii.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4521-0813</contrib-id><contrib-id contrib-id-type="spin">7329-0197</contrib-id><name-alternatives><name xml:lang="en"><surname>Galkina</surname><given-names>Anastasiia A.</given-names></name><name xml:lang="ru"><surname>Галкина</surname><given-names>Анастасия Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>anastasia.a.galkina@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-2223-1514</contrib-id><contrib-id contrib-id-type="spin">4207-9481</contrib-id><name-alternatives><name xml:lang="en"><surname>Bolyakina</surname><given-names>Darya K.</given-names></name><name xml:lang="ru"><surname>Болякина</surname><given-names>Дарья Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>bolyakina.dasha@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7678-2489</contrib-id><contrib-id contrib-id-type="spin">1883-8361</contrib-id><name-alternatives><name xml:lang="en"><surname>Parshina</surname><given-names>Veronika A.</given-names></name><name xml:lang="ru"><surname>Паршина</surname><given-names>Вероника Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>parshina.nicka@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8703-5686</contrib-id><contrib-id contrib-id-type="spin">2321-4718</contrib-id><name-alternatives><name xml:lang="en"><surname>Kurmasheva</surname><given-names>Renata A.</given-names></name><name xml:lang="ru"><surname>Курмашева</surname><given-names>Рената Адильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>renata.adilevna@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6444-6499</contrib-id><contrib-id contrib-id-type="spin">7555-5925</contrib-id><name-alternatives><name xml:lang="en"><surname>Shershakova</surname><given-names>Nadezda N.</given-names></name><name xml:lang="ru"><surname>Шершакова</surname><given-names>Надежда Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>д-р биол. наук</p></bio><email>nn.shershakova@nrcii.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4931-5380</contrib-id><contrib-id contrib-id-type="spin">4040-9486</contrib-id><name-alternatives><name xml:lang="en"><surname>Mikhina</surname><given-names>Larisa V.</given-names></name><name xml:lang="ru"><surname>Михина</surname><given-names>Лариса Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>larisa_mihina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4961-9640</contrib-id><contrib-id contrib-id-type="spin">3199-9803</contrib-id><name-alternatives><name xml:lang="en"><surname>Khaitov</surname><given-names>Musa R.</given-names></name><name xml:lang="ru"><surname>Хаитов</surname><given-names>Муса Рахимович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, corresponding member of Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, член-корр. РАН</p></bio><email>mr.khaitov@nrcii.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center for Toxicology and Hygienic Regulation of Biological Products — Branch of the National Research Center — Institute of Immunology Federal Medico-Biological Agency</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский центр токсикологии и гигиенической регламентации биопрепаратов — филиал Государственного научного центра «Институт иммунологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Research Center — Institute of Immunology Federal Medico-Biological Agency</institution></aff><aff><institution xml:lang="ru">Государственный научный центр «Институт иммунологии»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">The Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-04-07" publication-format="electronic"><day>07</day><month>04</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-06-03" publication-format="electronic"><day>03</day><month>06</month><year>2025</year></pub-date><volume>22</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>153</fpage><lpage>164</lpage><history><date date-type="received" iso-8601-date="2024-12-06"><day>06</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-03-18"><day>18</day><month>03</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ИД "АБВ-пресс"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">ИД "АБВ-пресс"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-06-03"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/16986">https://rusalljournal.ru/raj/article/view/16986</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold><italic>:</italic> The incidence of food allergy in adults and children is very high. The key approach in the therapy of food allergy can be quality drug selection. New synthetic derivatives of fullerene, a high-tech hydrocarbon, can become such drugs. A unique biocompatible method for obtaining a stable aqueous dispersion of fullerene C<sub>60</sub> <sub>(</sub>ADF-C<sub>60) </sub>as the main component for drugs for the treatment of allergic diseases has been developed.</p> <p>In this article, reproductive toxicity of the drug ADF-C<sub>60</sub>, currently in preclinical safety studies, was studied in female white outbred rats. Due to its properties, the ADF-C<sub>60</sub> is promising for treatment of food allergy and can presumably be used during pregnancy.</p> <p><bold>AIM</bold><italic>:</italic> Preclinical study of reproductive toxicity of an ADF-C<sub>60</sub> in the antenatal and postnatal periods of rat offspring development with oral administration to the mother generation during pregnancy.</p> <p><bold>MATERIALS AND METHODS</bold><italic>:</italic> Female rats were orally administered the ADF-C<sub>60</sub> in 1-, 5-, and 50-fold therapeutic doses recommended for humans during the whole pregnancy. The general parameters of embryotoxic and teratogenic effects of the ADF-C<sub>60</sub> before and after birth were studied.</p> <p><bold>RESULTS</bold><italic>:</italic> No evidence of embryotoxic and teratogenic effects of the ADF-C<sub>60</sub> was found during the study of gestational parameters and general fetuses development. No adverse effects of the ADF-C<sub>60</sub> were revealed during observation of postnatal development of offspring.</p> <p><bold>CONCLUSION</bold><italic>:</italic> ADF-C<sub>60</sub> for the treatment of food allergy has no reproductive toxicity at doses up to 50 times higher than the therapeutic dose. After the conducted experiments it is possible to assume a significant probability of using the ADF-C<sub>60</sub> during pregnancy, but additional preclinical and clinical studies are required to substantiate the obtained conclusion.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>.<italic> </italic>Распространенность пищевой аллергии среди взрослого и детского населения очень высока. Ключевым подходом к терапии пищевой аллергии может служить качественный подбор лекарственных средств. Разработан уникальный биосовместимый способ получения стабильной водной дисперсии фуллерена С<sub>60</sub> <sub>(</sub>ADF-C<sub>60) </sub>как основного компонента лекарственных препаратов для лечения аллергических заболеваний. На самках белых беспородных крыс изучена репродуктивная токсичность лекарственного средства ADF-C<sub>60</sub>, находящегося на этапе доклинических исследований безопасности. Благодаря своим свойствам данное лекарственное средство имеет потенциал для терапии пищевой аллергии, а также, предположительно, может использоваться в период беременности.</p> <p><bold>Цель</bold> — доклиническое исследование репродуктивной токсичности лекарственного средства ADF-C<sub>60</sub> в антенатальном и постнатальном периодах развития потомства крыс при пероральном введении материнскому поколению в течение беременности.</p> <p><bold>Материалы и методы</bold><italic>. </italic>Самкам крыс в течение всей беременности вводили перорально лекарственное средство ADF-C<sub>60</sub> в 1-, 5- и 50-кратной рекомендованной для человека терапевтической дозе. Изучали общие параметры эмбриотоксического и тератогенного действия лекарственного средства на потомство до и после его рождения.</p> <p>Результаты<italic>. </italic>На этапе исследования<italic> </italic>гестационного периода и общих характеристик плодов отсутствовали свидетельства эмбриотоксического и тератогенного эффектов лекарственного средства ADF-C<sub>60</sub>. В рамках наблюдения за постнатальным развитием потомства не выявлено отрицательных последствий от применения данного лекарственного средства.</p> <p><bold>Заключение</bold>.<italic> </italic>На основании полученных данных можно сделать выводы об отсутствии репродуктивной токсичности лекарственного средства ADF-C<sub>60</sub> для лечения пищевой аллергии в дозах, превышающих терапевтическую до 50 раз. Можно предположить существенную вероятность применения данного лекарственного средства при беременности, но для полноценного обоснования полученного заключения необходимы дополнительные доклинические и клинические исследования.</p></trans-abstract><kwd-group xml:lang="en"><kwd>food allergy</kwd><kwd>fullerene ADF-C60</kwd><kwd>rats</kwd><kwd>oral administration</kwd><kwd>embryotoxicity</kwd><kwd>teratogenicity</kwd><kwd>antenatal period</kwd><kwd>postnatal period</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пищевая аллергия</kwd><kwd>фуллерен ADF-C60</kwd><kwd>крысы</kwd><kwd>пероральное введение</kwd><kwd>эмбриотоксичность</kwd><kwd>тератогенность</kwd><kwd>антенатальный период</kwd><kwd>постнатальный период</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This study was carried out within the state assignment No. 22.008.24.800 in the Research Center for Toxicology and Hygienic Regulation of Biological Products — Branch of the National Research Center — Institute of Immunology Federal Medico-Biological Agency</funding-statement><funding-statement xml:lang="ru">Исследование выполнено в рамках государственного задания № 22.008.24.800 в Научно-исследовательском центре токсикологии и гигиенической регламентации биопрепаратов — филиале Государственного научного центра «Институт иммунологии»</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sidorovich OI, Luss LV. Food allergy principles of diagnosis and treatment. Medical Council. 2016;16:141–147. (In Russ.) doi: 10.21518/2079-701X-2016-16-141-147 EDN: WTOOZZ</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Балаболкин И.И. Пищевая аллергия у детей и подростков. Российский аллергологический журнал. 2006;3:44–52.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Новик Г.А. Пищевая аллергия у детей раннего возраста. Лечащий врач. 2011;4:54–60. EDN: SGRFKX</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health. 2018;15(9):2043. doi: 10.3390/ijerph15092043 EDN: SGPAIH</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Halken S, Muraro A, de Silva D, et al. EAACI guideline: preventing the development of food allergy in infants and young children (2020 update). Pediatr Allergy Immunol. 2021;32(5):843–858. doi: 10.1111/pai.13496 EDN: YLQDKD</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Prokopieva VD, Fedotova MM, Konovalova UV, et al. Prevalence and risk factors of food allergies in children: a review of epidemiological studies. Russian Journal of Allergy. 2022;19(2):175–189. (In Russ.) doi: 10.36691/RJA1531 EDN: TLVTGU</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Medzhidova MV, Abdullayeva NE, Fedorova NE, et al. Antiviral activity of amino acid derivatives of fullerene in cytomegalovirus infection in vitro. Antibiotics and Chemotherapy. 2004;49(8-9):13–20. (In Russ.) EDN: MQFJEN</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lin YL, Lei HY, Luh TY, et al. Light-independent inactivation of dengue-2 virus by carboxyfullerene C3 isomer. Virology. 2000;275(2):258–262. doi: 10.1006/viro.2000.0490</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tsao N, Luh TY, Chou CK, et al. In vitro action of carboxyfullerene. J Antimicrob Chemother. 2002;49(4):641–649. doi: 10.1093/jac/49.4.641 EDN: IQOPAB</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tsao N, Luh T, Chou C, et al. Inhibition of group A streptococcus infection by carboxyfullerene. Antimicrob Agents Chemother. 2001;45(6):1788–1793. doi: 10.1128/AAC.45.6.1788-1793.2001</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wang IC, Tai LA, Lee DD, et al. C60 and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. J Med Chem. 1999;42(22):4614–4620. doi: 10.1021/jm990144s</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Li W, Li N, Sui B, Yang D. Anti-aging effect of fullerenol on skin aging through derived stem cells in a mouse model. Exp Ther Med. 2017;14(5):5045–5050. doi: 10.3892/etm.2017.5163</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yang XL, Fan СH, Zhu HS. Photo-induced cytotoxicity of malonic acid C60 fullerene erivatives and its mechanism. Toxicol In Vitro. 2002;16(1):41–46. doi: 10.1016/s0887-2333(01)00102-3</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA. 1997;94(17):9434–9439. doi: 10.1073/pnas.94.17.9434</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Пиотровский Л.Б. Фуллерены в дизайне лекарственных веществ. Российские нанотехнологии. 2007;2(7-8):6–18. EDN: IADHGF</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sharoyko V, Shemchuk O, Meshcheriakov A, et al. Biocompatibility, antioxidant activity and collagen photoprotection properties of C60 fullerene adduct with L-methionine. Nanomedicine. 2022;40:102500. doi: 10.1016/j.nano.2021.102500 EDN: WOYHRZ</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Vesnina LE, Mamontova TV, Mikityuk MV, et al. The effect of fullerene C60 on the functional activity of phagocytic cells. Experimental and Clinical Pharmacology. 2011;74(6):26–29. (In Russ.) doi: 10.30906/0869-2092-2011-74-6-26-29 EDN: TNJZIF</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Andreev I, Petrukhina A, Garmanova A, et al. Penetration of fullerene C60 derivatives through biological membranes. Fullerenes, Nanotubes, and Carbon Nanostructures. 2008;16(2):89–102. doi: 10.1080/15363830701885831 EDN: LLJKIZ</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003;38(11-12):913–923. doi: 10.1016/j.ejmech.2003.09.005</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Roursgaard M, Poulsen SS, Kepley CL, et al. Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice. Basic Clin Pharmacol Toxicol. 2008;103(4):386–388. doi: 10.1111/j.1742-7843.2008.00315.x</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Deguchi Sh, Mukai SA. Top-down preparation of dispersions of C60 nanoparticles in organic solvents. Chem Lett. 2006;35(4):396–397. doi: 10.1246/cl.2006.396 EDN: XPDWYH</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gupta SK, Dhawan A, Shanker R. In silico approaches: prediction of biological targets for fullerene derivatives. J Biomed Nanotech. 2011;7(1):91–92. doi: 10.1166/jbn.2011.1217</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fujii-Kuriyama Y, Mimura J. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem Biophys Res Commun. 2005;338(1):311–317. doi: 10.1016/j.bbrc.2005.08.162</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Andreev S, Purgina D, Bashkatova E, et al. Study of fullerene aqueous dispersion prepared by novel dialysis method: simple way to fullerene aqueous solution. Fullerenes Nanotubes and Carbon Nanostructures. 2015;23(9):792–800. doi: 10.1080/1536383X.2014.998758 EDN: TWXIEX</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Gharbi N, Pressac M, Hadchouel M, et al. Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5(12):2578–2585. doi: 10.1021/nl051866b EDN: LQQJGL</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shershakova NN, Andreev SM, Tomchuk AA, et al. Wound healing activity of aqueous dispersion of fullerene C60 produced by “green technology”. Nanomedicine. 2023;47:102619. doi: 10.1016/j.nano.2022.102619 EDN: KUQAEO</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Shershakova N, Baraboshkina E, Andreev S, et al. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnol. 2016;14:8. doi: 10.1186/s12951-016-0159-z EDN: VFVUPH</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Andreev SM, Bashkatova EN, Purgina DD, et al. Fullerenes: biomedical aspects. Immunologiya. 2015;36(1):57–61. (In Russ.) EDN: TNIIGP</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Руководство по проведению доклинических исследований лекарственных средств. Часть Первая / под ред. А.Н. Миронова, Н.Д. Бунятян, А.Н. Васильева, и др. Москва: Гриф и К, 2012. 944 с. ISBN: 978-5-8125-1466-3</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Руководство по содержанию и использованию лабораторных животных / под ред. И.В. Белозерцевой, М.С. Красильщиковой. 8-е изд. М.: ИРБИС, 2017. 336 с. ISBN: 978-5-9909917-0-5</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Kovaleva EV, Rybalkin SP, Shangaraeva VA, et al. Study of reproductive toxicity of the recombinant allergy vaccine for the treatment of allergy to birch pollen and cross-related allergens. Immunologiya. 2023;44(6):721–730. (In Russ.) doi: 10.33029/0206-4952-2023-44-6-721-730 EDN: HHPANS</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728–745. doi: 10.1111/pai.12807</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Krishna SS, Farhana SA, TPA, et al. Modulation of immune response by nanoparticle-based immunotherapy against food allergens. Front Immunol. 2023;14:1229667. doi: 10.3389/fimmu.2023.1229667 EDN: PQLDRQ</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Ryan JJ, Bateman HR, Stover A, et al. Fullerene nanomaterials inhibit the allergic response. J Immunol. 2007;179(1):665–672. doi: 10.4049/jimmunol.179.1.665</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Шершакова Н.Н. Фуллерен C60: механизм биологической активности и разработка подходов к терапии заболеваний, связанных с окислительным стрессом: автореф. дис. … д-ра биол. наук: 3.2.7 — Иммунология. Москва: ФГБУ «ГНЦ «Институт иммунологии», 2024. 48 с. EDN: QCAGPV</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Takahashi M, Kato H, Doi Y, et al. Sub-acute oral toxicity study with fullerene C60 in rats. J Toxicol Sci. 2012;37(2):353–361. doi: 10.2131/jts.37.35338 EDN: PHPPST</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Чернух А.М., Александров П.Н. О тератогенном действии химических (лекарственных) веществ. Москва: Медицина, 1969. 176 с.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Юшков Б.Г., Корнева Е.А., Черешнев В.А. Понятие нормы в физиологии и патологии. Физиологические константы лабораторных животных. Екатеринбург: УрО РАН, 2021. 864 с. ISBN: 978-5-7691-2542-3 EDN: XHQGVO</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Aliverti V, Bonanomi L, Giavini E, et al. The extent of fetal ossification as an index of delayed development in teratogenic studies on the rat. Teratology. 1979;20(2):237–242. doi: 10.1002/tera.1420200208</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Физические, биохимические и биометрические показатели нормы экспериментальных животных. Справочник / под ред. В.Г. Макарова, М.Н. Макаровой. Санкт-Петербург: Изд-во «Лема», 2013. 116 с. ISBN: 978-5-98709-619-2</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Guidance document on mammalian reproductive toxicity testing and assessment. OECD Environment, Health and Safety Publications. Series on Testing and Assessment [Internet]. 2008;43. Available from: https://www.oecd.org/en/publications/2008/07/guidance-document-on-mammalian-reproductive-toxicity-testing-and-assessment_02d2bf6d.html</mixed-citation></ref></ref-list></back></article>
